Gilead set to acquire German biotech firm MYR in about €1.15billion deal

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S.

Gilead Sciences Inc said on Thursday it will acquire German biotech company MYR GmbH for about 1.15 billion euros (an equivalent of $1.39 billion) in cash.

The deal, which will also include a potential future milestone payment of up to 300 million euros, will give Gilead access to Hepcludex, MYR’s treatment for chronic hepatitis delta virus, or HDV, infection.

Hepcludex was conditionally approved by the European Medicines Agency in July.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s